Medical Educational Resource
The role of complement in ALS and the MERIDIAN study of pegcetacoplan in sporadic ALS
This Industry Update Webinar is sponsored by Apellis. This program is not sponsored, endorsed, or accredited by MDA.
This webinar discusses the role of complement mediated neuroinflammation and complement component C3 in ALS disease and progression followed by an overview of the ongoing Phase 2, placebo controlled, study of the C3 inhibitor pegcetacoplan in ALS. The featured presenter of this Industry Update Webinar is Dr. Rup Tandan from the University of Vermont Medical Center. This Industry Update Webinar is sponsored by Apellis.